GLP-1 weight-loss drugs alter brain circuits in the amygdala and dopamine system to reduce the motivation to seek out high-calorie foods.

A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.

A study has found that an emerging class of GLP-1 weight-loss drugs suppresses eating for pleasure, or hedonic feeding, in ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with a lower risk of developing new substance use disorders.

Newer oral weight loss drugs could be doing more than only suppressing appetite -- they may also be directly altering brain ...

A University of Virginia study published in Nature reveals that oral GLP-1 weight-loss drugs not only suppress appetite but also alter brain circuits that govern motivation and reward. Researchers ...

Drug addiction poses a global public health challenge, with limited therapeutic options and modest efficacy. While numerous studies have shown that social status profoundly impacts mental health and ...

University of Virginia researchers have shown that newer oral GLP-1 weight-loss drugs directly alter brain circuits tied to motivation and reward, not just appetite. These medications engage a pathway ...